Skip to main content
Premium Trial:

Request an Annual Quote

Genzyme Diagnostics Forgoes Access to Future Syn-X Technologies in Effort to Resolve Dispute

NEW YORK, July 11 – Genzyme Diagnostics no longer has first offer rights to future technologies developed by Syn-X Pharma, following an agreement that resolves previous disputes between the two companies.

In a statement issued on Tuesday, Genzyme and Syn-X announced that Genzyme would continue to develop a stroke panel called NeuroTrak, while Syn-X would retain rights to future royalty payments based on product sales.

Genzyme, however, is no longer obligated to make financial obligations to Syn-X and no longer has special rights to the Canadian proteomics company’s technology.

"The new agreement is a win-win situation," Sean McNicholas, CEO of SYN-X, said in a statement. "It allows Genzyme to continue to develop the stroke technology and SYN-X the opportunity to focus on accelerating the development of our pipeline products." 

Genzyme Diagnostics said it expected to complete clinical trials of the new stroke panel in 2003.

Genzyme Diagnostics of Cambridge, Mass., is a business unit of Genzyme General. Syn-X is based in Mississauga, Ontario. It has developed the Proteomics Discovery Platform, a technology that can be used to identify drug targets as well as to develop specialized antibody-based diagnostics. 

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.